<?xml version="1.0" encoding="UTF-8"?>
<p id="p0025">Remdesivir remains the most promising drug to treat the Ebola virus 
 <xref rid="b0025" ref-type="bibr">[6]</xref> infection and has the ability to inhibit replication of SARS-CoV and MERS-CoV in tissue culture and in non-human animal models. According to a recent press release, the last patient suffering from Ebola virus in Democratic Republic of Congo has been released from the hospital. Lopinavir/Ritonavir and interferon Î² (LPV/RTV-INFb) form another combination drug also available, but clinical trials on a humanized mice model have shown that Remdesivir is a better drug to treat MERS-CoV 
 <xref rid="b0025" ref-type="bibr">[6]</xref>, 
 <xref rid="b0030" ref-type="bibr">[7]</xref>. In another study in South Korea, Lopinavir/Ritonavir (Kaletra, Abbvie) was administered to patients suffering from Covid-19. Following treatment, viral loads were found to be significantly decreased, and no or little Coronavirus titres were observed 
 <xref rid="b0035" ref-type="bibr">[8]</xref>.
</p>
